Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depression, Bipolar Depression, Major Depressive Disorder
Interventions: Low Field Magnetic Stimulation Device; Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder, Mood Disorders
Interventions: Rumination-Focused CBT, Relaxation-based Therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 14 Years to 17 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Columbus, Ohio • Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: real-time fMRI neurofeedback: Amygdala, real-time fMRI neurofeedback: HIPS; Behavioral
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Depressive Disorder, Major Depressive Disorder
Interventions: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 7 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 9
States / cities: Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more

Conditions: Major Depressive Disorder
Interventions: AV-101, Placebo; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Garden Grove, California • Los Angeles, California • National City, California + 18 more

Conditions: Major Depressive Disorder
Interventions: apimostinel, Placebo; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Major Depressive Disorder
Interventions: Open-label TMS; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: desvenlafaxine SR, venlafaxine ER; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Depression, Suicidal Ideation, Major Depressive Disorder, Depressive Disorder
Interventions: "Engage & Connect" Psychotherapy, Symptom Review and Psychoeducation (SRP); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation, Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC; Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depression
Interventions: citalopram + tiodothyronine, or + pindolol, or + placebo; Drug
Lead sponsor: Mark Frye; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder, Epilepsy, Mood
Interventions: Intracranial EEG monitoring with audio-video recording; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depressive Disorder, Major Depressive Episode
Interventions: Universal Screening Arm; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Not listed
Enrollment: 12,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Major Depressive Disorder, Recurrent
Interventions: Mindfulness Based Cognitive Therapy, Health Enhancement Program; Behavioral
Lead sponsor: University of Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions: Nitrous Oxide 25%, Nitrous Oxide 50%, Placebo Gas; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Brain stimulation; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Placebo, JNJ-42847922; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Anaheim, California • Chino, California • Lemon Grove, California + 24 more

Conditions: Major Depressive Disorder, Overweight, Inflammation
Interventions: Placebo, EPA 1 g/day, EPA 2 g/day, EPA 4 g/day; Other · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Major Depressive Disorder (MDD), Suicidal Ideation
Interventions: TMS; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 15 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
Interventions: Be Mindful; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Major Depressive Disorder
Interventions: Bupropion XL 300; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: eicosapentaenoic acid, docosahexaenoic acid, Placebo; Dietary Supplement · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Behavioral activation plus mobile app, Standard behavioral activation; Behavioral
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: North Little Rock, Arkansas

Conditions: Major Depressive Disorder, Irritability
Interventions: Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 15
States / cities: Tucson, Arizona • Glendale, California • Oakland, California + 12 more

Search by objective public record fields.

Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device

Mechanisms of Rumination Change in Adolescent Depression

Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

In-patient SCC TMS

Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects

Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression

Can Additional Drug Therapy Accelerate Response Time to Antidepressants

Behavioral and Neuronal Correlates of Human Mood States

Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder

The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms

Clinical Study of Generic and Brand Bupropion in Depression

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

Mobile Apps for the Treatment of Depression

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy